TY  - CONF
AU  - Gašić, Vladimir
AU  - Pravdić, Zlatko
AU  - Suvajdžić Vuković, Nada
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1899
AB  - Acute myeloid leukemia (AML) is a malignancy of hematopoetic tissue which occurs due to a halt in
differentiation, loss of proliferation control and dysregulated apoptosis of myeloid progenitor cells. In
many cancers, as well as AML, dysregulation of apoptosis constitutes the basis of pathogenesis and this
phenomenon is important for chemotherapy success. Pharmacotranscriptomic markers of AML
prognosis could be targets of specific therapy. The anti-apoptotic gene BCL2 (B-cell lymphoma protein
2), the pro-apoptotic BAX (BCL2-associated X) and genes involved in drug resistance, like MDR1
could have a significant impact on AML prognosis and therapy response. Bone-marrow samples at
diagnosis were collected from 51 adult patients with AML-NK. Expressions of BCL2, BAX and MDR1
were analysed using the real-time polymerase chain reaction method. Statistical evaluation was
performed. The presence of chemoresistance was found to be associated with overexpression of BCL2
(BCL2+) (p=0.018), while underexpression of BAX in patients has shown a greater affinity towards
relapse (p=0.034). Evaluating the expressions of BCL2 and BAX in a combined effect has shown that
87% of patients with BAX/BCL2low status were resistant to therapy (p=0.024). BCL2+ status was
associated with high expression of MDR1 (p<0.001). Likewise, high expression of MDR1 was
associated with the absence of NPM1 and FLT3-ITD mutations (p=0.048 and p=0.010, respectively).
This is the first study that focused only on AML-NK patients, when it comes to analysis of BCL2, BAX
and MDR1 gene expression profiles. The results of this preliminary study have shown that high BCL2
expression would likely lead to resistance from chemotherapy, making anti-BCL2 treatment a viable
option in patients with this expression profile. A study on a larger group of patients could clarify the
prognostic importance of the studied genes in adult AML-NK patients and improve the precision
medicine approach in the field of hematology.
PB  - Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo
C3  - Genetics & Applications
T1  - Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia
VL  - 7
VL  - 2 (Special edition)
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1899
ER  - 

@conference{
author = "Gašić, Vladimir and Pravdić, Zlatko and Suvajdžić Vuković, Nada and Marjanović, Irena and Karan-Đurašević, Teodora and Pavlović, Sonja and Tošić, Nataša",
year = "2023",
abstract = "Acute myeloid leukemia (AML) is a malignancy of hematopoetic tissue which occurs due to a halt in
differentiation, loss of proliferation control and dysregulated apoptosis of myeloid progenitor cells. In
many cancers, as well as AML, dysregulation of apoptosis constitutes the basis of pathogenesis and this
phenomenon is important for chemotherapy success. Pharmacotranscriptomic markers of AML
prognosis could be targets of specific therapy. The anti-apoptotic gene BCL2 (B-cell lymphoma protein
2), the pro-apoptotic BAX (BCL2-associated X) and genes involved in drug resistance, like MDR1
could have a significant impact on AML prognosis and therapy response. Bone-marrow samples at
diagnosis were collected from 51 adult patients with AML-NK. Expressions of BCL2, BAX and MDR1
were analysed using the real-time polymerase chain reaction method. Statistical evaluation was
performed. The presence of chemoresistance was found to be associated with overexpression of BCL2
(BCL2+) (p=0.018), while underexpression of BAX in patients has shown a greater affinity towards
relapse (p=0.034). Evaluating the expressions of BCL2 and BAX in a combined effect has shown that
87% of patients with BAX/BCL2low status were resistant to therapy (p=0.024). BCL2+ status was
associated with high expression of MDR1 (p<0.001). Likewise, high expression of MDR1 was
associated with the absence of NPM1 and FLT3-ITD mutations (p=0.048 and p=0.010, respectively).
This is the first study that focused only on AML-NK patients, when it comes to analysis of BCL2, BAX
and MDR1 gene expression profiles. The results of this preliminary study have shown that high BCL2
expression would likely lead to resistance from chemotherapy, making anti-BCL2 treatment a viable
option in patients with this expression profile. A study on a larger group of patients could clarify the
prognostic importance of the studied genes in adult AML-NK patients and improve the precision
medicine approach in the field of hematology.",
publisher = "Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo",
journal = "Genetics & Applications",
title = "Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia",
volume = "7, 2 (Special edition)",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1899"
}

Gašić, V., Pravdić, Z., Suvajdžić Vuković, N., Marjanović, I., Karan-Đurašević, T., Pavlović, S.,& Tošić, N.. (2023). Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia. in Genetics & Applications
Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo., 7.
https://hdl.handle.net/21.15107/rcub_imagine_1899

Gašić V, Pravdić Z, Suvajdžić Vuković N, Marjanović I, Karan-Đurašević T, Pavlović S, Tošić N. Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia. in Genetics & Applications. 2023;7.
https://hdl.handle.net/21.15107/rcub_imagine_1899 .

Gašić, Vladimir, Pravdić, Zlatko, Suvajdžić Vuković, Nada, Marjanović, Irena, Karan-Đurašević, Teodora, Pavlović, Sonja, Tošić, Nataša, "Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia" in Genetics & Applications, 7 (2023),
https://hdl.handle.net/21.15107/rcub_imagine_1899 .

TY  - CONF
AU  - Đorđe, Pavlović
AU  - Tošić, Nataša
AU  - Zukić, Branka
AU  - Pravić, Zlatko
AU  - Suvajdžić Vuković, Nada
AU  - Pavlović, Sonja
AU  - Gašić, Vladimir
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2127
AB  - Introduction: Acute myeloid leukemia (AML) is a heterogeneous malignant disease, that accounts for
80% of all acute leukemias in adults. Imprecise risk stratification and lack of personalized treatment creates a constant need to find new prognostic markers and targets for innovative therapeutics. Recently,
thissearch has pointed towards non-coding RNAs(ncRNA). Numerousstudies have shown dysregulation
of lncRNA GAS5 in cancers, but it was poorly investigated in AML. Since GAS5 actslike a molecularsponge
for miR-222, co-expression profiles of these non-coding RNAs could be novel prognostic markersin AML.
Methods: GAS5 expression levels were analysed in 94 AML patients and 14 healthy controls using RealTime PCR and miR-222 expression levels were analysed in a subgroup of 39 patients with normal karyotype (AML-NK). ROC curve analyses were used to find a cut-off value between GAS5high and GAS5low,
while the median value was used for distinguishing between miR-222high and miR-222low.
Results: We showed that GAS5 expression in AML patients was lower compared to healthy controls.
Lower GAS5 expression on diagnosis was related to an adverse prognosis. The disease-free survival and
the overallsurvival were lower in the GAS5low group butsurvival analysisfailed to confirm thisfinding. In
the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic
effect of GAS5low/miR-222high status on disease prognosis was not established.
Conclusion:Our findingsindicate the potential prognostic significance of GAS5 expression and the need
for further investigation of these two non-coding RNAs and their potential roles in leukemogenesis.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Expression profiles of long non-coding RNA gas5 and microrna-222 in younger AML patients
EP  - 72
SP  - 72
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2127
ER  - 

@conference{
author = "Đorđe, Pavlović and Tošić, Nataša and Zukić, Branka and Pravić, Zlatko and Suvajdžić Vuković, Nada and Pavlović, Sonja and Gašić, Vladimir",
year = "2023",
abstract = "Introduction: Acute myeloid leukemia (AML) is a heterogeneous malignant disease, that accounts for
80% of all acute leukemias in adults. Imprecise risk stratification and lack of personalized treatment creates a constant need to find new prognostic markers and targets for innovative therapeutics. Recently,
thissearch has pointed towards non-coding RNAs(ncRNA). Numerousstudies have shown dysregulation
of lncRNA GAS5 in cancers, but it was poorly investigated in AML. Since GAS5 actslike a molecularsponge
for miR-222, co-expression profiles of these non-coding RNAs could be novel prognostic markersin AML.
Methods: GAS5 expression levels were analysed in 94 AML patients and 14 healthy controls using RealTime PCR and miR-222 expression levels were analysed in a subgroup of 39 patients with normal karyotype (AML-NK). ROC curve analyses were used to find a cut-off value between GAS5high and GAS5low,
while the median value was used for distinguishing between miR-222high and miR-222low.
Results: We showed that GAS5 expression in AML patients was lower compared to healthy controls.
Lower GAS5 expression on diagnosis was related to an adverse prognosis. The disease-free survival and
the overallsurvival were lower in the GAS5low group butsurvival analysisfailed to confirm thisfinding. In
the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic
effect of GAS5low/miR-222high status on disease prognosis was not established.
Conclusion:Our findingsindicate the potential prognostic significance of GAS5 expression and the need
for further investigation of these two non-coding RNAs and their potential roles in leukemogenesis.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Expression profiles of long non-coding RNA gas5 and microrna-222 in younger AML patients",
pages = "72-72",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2127"
}

Đorđe, P., Tošić, N., Zukić, B., Pravić, Z., Suvajdžić Vuković, N., Pavlović, S.,& Gašić, V.. (2023). Expression profiles of long non-coding RNA gas5 and microrna-222 in younger AML patients. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 72-72.
https://hdl.handle.net/21.15107/rcub_imagine_2127

Đorđe P, Tošić N, Zukić B, Pravić Z, Suvajdžić Vuković N, Pavlović S, Gašić V. Expression profiles of long non-coding RNA gas5 and microrna-222 in younger AML patients. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:72-72.
https://hdl.handle.net/21.15107/rcub_imagine_2127 .

Đorđe, Pavlović, Tošić, Nataša, Zukić, Branka, Pravić, Zlatko, Suvajdžić Vuković, Nada, Pavlović, Sonja, Gašić, Vladimir, "Expression profiles of long non-coding RNA gas5 and microrna-222 in younger AML patients" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):72-72,
https://hdl.handle.net/21.15107/rcub_imagine_2127 .

TY  - CONF
AU  - Pavlović, Đorđe
AU  - Tošić, Nataša
AU  - Zukić, Branka
AU  - Pravdić, Zlatko
AU  - Suvajdžić Vuković, Nada
AU  - Pavlović, Sonja
AU  - Gašić, Vladimir
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1742
AB  - Akutna mijeloidna leukemija (AML) je heterogeno maligno oboljenje kako na
kliničkom tako i na genetičkom nivou. AML ima lošu prognozu, i zato postoji
konstantna potreba za novim prognostičkim markerima, kao i markerima koji
mogu biti mete za inovativne terapeutike. U skorije vreme potraga za novim
biomarkerima je naučnicima skrenula pažnju ka nekodirajućim RNK, naročito
dugim nekodirajućim RNK (dnkRNK) i mikroRNK (miRNK). U ovom radu ispitali
smo nivo ekspresije „growth arrest-specific transcript 5“ (GAS5) dnkRNK kod 94
mlađih osoba obolelih od AML, kao i nivo ekspresije miR-222 u grupi od 39
osoba obolelih od AML sa normalnim kariotipom (AML-NK), u cilju da
ispitamo njihov prognostički potencijal. Naši rezultati su pokazali da je nivo
ekspresije GAS5 kod obolelih od AML niži u poređenju sa zdravim kontrolama, i
češći je u grupi sa nepovoljnom prognozom. U AML-NK grupi pacijenti su imali
povišenu ekspresiju miR-222 u poređenju sa zdravim kontrolama. Sinergistički
efekat „GAS5low/miR-222 high“ nije utvrđen. Ovo je prva studija koja je ispitala
interakciju ekspresije GAS5 i miR-222 kod obolelih od AML. Naši rezultati
indikuju potrebu za daljim ispitivanjem ove dve nekodirajuće RNK i njihove
potencijalne uloge u leukemogenezi i prognostici AML pacijenata.
AB  - Акутна мијелоидна леукемија (АМЛ) је хетерогено малигно обољење како на
клиничком тако и на генетичком нивоу. АМЛ има лошу прогнозу, и зато постоји
константна потреба за новим прогностичким маркерима, као и маркерима који
могу бити мете за иновативне терапеутике. У скорије време потрага за новим
биомаркерима је научницима скренула пажњу ка некодирајућим РНК, нарочито
дугим некодирајућим РНК (днкРНК) и микроРНК (миРНК). У овом раду испитали
смо ниво експресије „growth arrest-specific transcript 5“ (GAS5) днкРНК код 94
млађих особа оболелих од АМЛ, као и ниво експресије miR-222 у групи од 39
особа оболелих од АМЛ са нормалним кариотипом (АМЛ-НК), у циљу да
испитамо њихов прогностички потенцијал. Наши резултати су показали да је ниво
експресије GAS5 код оболелих од АМЛ нижи у поређењу са здравим контролама, и
чешћи је у групи са неповољном прогнозом. У АМЛ-НК групи пацијенти су имали
повишену експресију miR-222 у поређењу са здравим контролама. Синергистички
ефекат „GAS5low/miR-222 high“ није утврђен. Ово је прва студија која је испитала
интеракцију експресије GAS5 и miR-222 код оболелих од АМЛ. Наши резултати
индикују потребу за даљим испитивањем ове две некодирајуће РНК и њихове
потенцијалне улоге у леукемогенези и прогностици АМЛ пацијената.
PB  - Beograd : Srpsko biološko društvo
C3  - Treći kongres biologa Srbije
T1  - Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML
T1  - Експресиони образац дуге некодирајуће РНК GAS5 и микроРНК- 222 код млађих пацијената оболелих од АМЛ
SP  - 302
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1742
ER  - 

@conference{
author = "Pavlović, Đorđe and Tošić, Nataša and Zukić, Branka and Pravdić, Zlatko and Suvajdžić Vuković, Nada and Pavlović, Sonja and Gašić, Vladimir",
year = "2022",
abstract = "Akutna mijeloidna leukemija (AML) je heterogeno maligno oboljenje kako na
kliničkom tako i na genetičkom nivou. AML ima lošu prognozu, i zato postoji
konstantna potreba za novim prognostičkim markerima, kao i markerima koji
mogu biti mete za inovativne terapeutike. U skorije vreme potraga za novim
biomarkerima je naučnicima skrenula pažnju ka nekodirajućim RNK, naročito
dugim nekodirajućim RNK (dnkRNK) i mikroRNK (miRNK). U ovom radu ispitali
smo nivo ekspresije „growth arrest-specific transcript 5“ (GAS5) dnkRNK kod 94
mlađih osoba obolelih od AML, kao i nivo ekspresije miR-222 u grupi od 39
osoba obolelih od AML sa normalnim kariotipom (AML-NK), u cilju da
ispitamo njihov prognostički potencijal. Naši rezultati su pokazali da je nivo
ekspresije GAS5 kod obolelih od AML niži u poređenju sa zdravim kontrolama, i
češći je u grupi sa nepovoljnom prognozom. U AML-NK grupi pacijenti su imali
povišenu ekspresiju miR-222 u poređenju sa zdravim kontrolama. Sinergistički
efekat „GAS5low/miR-222 high“ nije utvrđen. Ovo je prva studija koja je ispitala
interakciju ekspresije GAS5 i miR-222 kod obolelih od AML. Naši rezultati
indikuju potrebu za daljim ispitivanjem ove dve nekodirajuće RNK i njihove
potencijalne uloge u leukemogenezi i prognostici AML pacijenata., Акутна мијелоидна леукемија (АМЛ) је хетерогено малигно обољење како на
клиничком тако и на генетичком нивоу. АМЛ има лошу прогнозу, и зато постоји
константна потреба за новим прогностичким маркерима, као и маркерима који
могу бити мете за иновативне терапеутике. У скорије време потрага за новим
биомаркерима је научницима скренула пажњу ка некодирајућим РНК, нарочито
дугим некодирајућим РНК (днкРНК) и микроРНК (миРНК). У овом раду испитали
смо ниво експресије „growth arrest-specific transcript 5“ (GAS5) днкРНК код 94
млађих особа оболелих од АМЛ, као и ниво експресије miR-222 у групи од 39
особа оболелих од АМЛ са нормалним кариотипом (АМЛ-НК), у циљу да
испитамо њихов прогностички потенцијал. Наши резултати су показали да је ниво
експресије GAS5 код оболелих од АМЛ нижи у поређењу са здравим контролама, и
чешћи је у групи са неповољном прогнозом. У АМЛ-НК групи пацијенти су имали
повишену експресију miR-222 у поређењу са здравим контролама. Синергистички
ефекат „GAS5low/miR-222 high“ није утврђен. Ово је прва студија која је испитала
интеракцију експресије GAS5 и miR-222 код оболелих од АМЛ. Наши резултати
индикују потребу за даљим испитивањем ове две некодирајуће РНК и њихове
потенцијалне улоге у леукемогенези и прогностици АМЛ пацијената.",
publisher = "Beograd : Srpsko biološko društvo",
journal = "Treći kongres biologa Srbije",
title = "Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML, Експресиони образац дуге некодирајуће РНК GAS5 и микроРНК- 222 код млађих пацијената оболелих од АМЛ",
pages = "302",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1742"
}

Pavlović, Đ., Tošić, N., Zukić, B., Pravdić, Z., Suvajdžić Vuković, N., Pavlović, S.,& Gašić, V.. (2022). Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML. in Treći kongres biologa Srbije
Beograd : Srpsko biološko društvo., 302.
https://hdl.handle.net/21.15107/rcub_imagine_1742

Pavlović Đ, Tošić N, Zukić B, Pravdić Z, Suvajdžić Vuković N, Pavlović S, Gašić V. Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML. in Treći kongres biologa Srbije. 2022;:302.
https://hdl.handle.net/21.15107/rcub_imagine_1742 .

Pavlović, Đorđe, Tošić, Nataša, Zukić, Branka, Pravdić, Zlatko, Suvajdžić Vuković, Nada, Pavlović, Sonja, Gašić, Vladimir, "Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML" in Treći kongres biologa Srbije (2022):302,
https://hdl.handle.net/21.15107/rcub_imagine_1742 .

TY  - JOUR
AU  - Pavlović, Đorđe
AU  - Tošić, Nataša
AU  - Zukić, Branka
AU  - Pravdić, Zlatko
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Gašić, Vladimir
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1573
AB  - Acute myeloid leukemia (AML) is a heterogeneous malignant disease both on clinical and genetic levels. AML has poor prognosis and, therefore, there is a constant need to find new prognostic markers, as well as markers that can be used as targets for innovative therapeutics. Recently, the search for new biomarkers has turned researchers' attention towards non-coding RNAs, especially long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). We investigated the expression level of growth arrest-specific transcript 5 (GAS5) lncRNA in 94 younger AML patients, and also the expression level of miR-222 in a cohort of 39 AML patients with normal karyotype (AML-NK), in order to examine their prognostic potential. Our results showed that GAS5 expression level in AML patients was lower compared to healthy controls. Lower GAS5 expression on diagnosis was related to an adverse prognosis. In the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic effect of GAS5(low)/miR-222(high) status on disease prognosis was not established. This is the first study focused on examining the GAS5 and miR-222 expression pattern in AML patients. Its initial findings indicate the need for further investigation of these two non-coding RNAs, their potential roles in leukemogenesis, and the prognosis of AML patients.
PB  - MDPI, Basel
T2  - Diagnostics
T1  - Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients
IS  - 1
VL  - 12
DO  - 10.3390/diagnostics12010086
ER  - 

@article{
author = "Pavlović, Đorđe and Tošić, Nataša and Zukić, Branka and Pravdić, Zlatko and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Gašić, Vladimir",
year = "2022",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous malignant disease both on clinical and genetic levels. AML has poor prognosis and, therefore, there is a constant need to find new prognostic markers, as well as markers that can be used as targets for innovative therapeutics. Recently, the search for new biomarkers has turned researchers' attention towards non-coding RNAs, especially long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). We investigated the expression level of growth arrest-specific transcript 5 (GAS5) lncRNA in 94 younger AML patients, and also the expression level of miR-222 in a cohort of 39 AML patients with normal karyotype (AML-NK), in order to examine their prognostic potential. Our results showed that GAS5 expression level in AML patients was lower compared to healthy controls. Lower GAS5 expression on diagnosis was related to an adverse prognosis. In the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic effect of GAS5(low)/miR-222(high) status on disease prognosis was not established. This is the first study focused on examining the GAS5 and miR-222 expression pattern in AML patients. Its initial findings indicate the need for further investigation of these two non-coding RNAs, their potential roles in leukemogenesis, and the prognosis of AML patients.",
publisher = "MDPI, Basel",
journal = "Diagnostics",
title = "Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients",
number = "1",
volume = "12",
doi = "10.3390/diagnostics12010086"
}

Pavlović, Đ., Tošić, N., Zukić, B., Pravdić, Z., Suvajdžić-Vuković, N., Pavlović, S.,& Gašić, V.. (2022). Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients. in Diagnostics
MDPI, Basel., 12(1).
https://doi.org/10.3390/diagnostics12010086

Pavlović Đ, Tošić N, Zukić B, Pravdić Z, Suvajdžić-Vuković N, Pavlović S, Gašić V. Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients. in Diagnostics. 2022;12(1).
doi:10.3390/diagnostics12010086 .

Pavlović, Đorđe, Tošić, Nataša, Zukić, Branka, Pravdić, Zlatko, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Gašić, Vladimir, "Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients" in Diagnostics, 12, no. 1 (2022),
https://doi.org/10.3390/diagnostics12010086 . .

TY  - JOUR
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Tatjana
AU  - Virijević, Marijana
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1506
AB  - Introduction Acute myeloid leukemia with normal karyotype (AML-NK) is the largest group of AML patients with very heterogeneous disease outcome. In order to ensure more precise risk stratification new molecular markers have been introduced, like expression level for BAALC (Brain and Acute Leukemia, Cytoplasmic) and MN1 (Meningioma 1) genes. Methods In this study, we investigated expression level of both genes in 111 adult AML-NK at diagnosis and examined their prognostic potential. Results BAALC and MN1 expression were detected in about one third of the patients, and positive correlation between these two genes was found. The BAALC(+)/or MN1(+) status was not associated with the presence of FLT3-ITD mutations, but exhibited strong correlation with NPM1(wt) status (P  lt  .001). Therefore, among BAALC(+)/or MN1(+) patients the most frequent ones were FLT3-ITD-/NPM1(-) double negative patients with intermediate prognosis. When BAALC(+)/or MN1(+) patients were divided into BAALC(high)/BAALC(low) (21/21) and MN1(high)/MN1(low) (21/22) groups, we detected that BAALC(high)/or MN1(high) patients had a tendency toward lower complete remission rate. Also, survival analysis showed that BAALC(high)/or MN1(high) patients had shorter disease-free survival and overall survival (OS). The most pronounced influence on prognosis was detected in FLT3-ITD-/NPM1(-) group of patients that are lacking reliable prognostic markers, where OS in BAALC(high)/or MN1(high) was only 5 months vs 25 months in BAALC(low)/or MN1(low). Conclusion These findings indicate that BAALC and MN1 expression level could be used for more precise risk stratification of AML-NK patients and especially FLT3-ITD-/NPM1(-) patients, transforming this intermediate-risk group, into a group with an adverse prognosis.
PB  - Wiley, Hoboken
T2  - International Journal of Laboratory Hematology
T1  - Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype
EP  - 440
IS  - 3
SP  - 433
VL  - 43
DO  - 10.1111/ijlh.13405
ER  - 

@article{
author = "Marjanović, Irena and Karan-Đurašević, Teodora and Kostić, Tatjana and Virijević, Marijana and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Tošić, Nataša",
year = "2021",
abstract = "Introduction Acute myeloid leukemia with normal karyotype (AML-NK) is the largest group of AML patients with very heterogeneous disease outcome. In order to ensure more precise risk stratification new molecular markers have been introduced, like expression level for BAALC (Brain and Acute Leukemia, Cytoplasmic) and MN1 (Meningioma 1) genes. Methods In this study, we investigated expression level of both genes in 111 adult AML-NK at diagnosis and examined their prognostic potential. Results BAALC and MN1 expression were detected in about one third of the patients, and positive correlation between these two genes was found. The BAALC(+)/or MN1(+) status was not associated with the presence of FLT3-ITD mutations, but exhibited strong correlation with NPM1(wt) status (P  lt  .001). Therefore, among BAALC(+)/or MN1(+) patients the most frequent ones were FLT3-ITD-/NPM1(-) double negative patients with intermediate prognosis. When BAALC(+)/or MN1(+) patients were divided into BAALC(high)/BAALC(low) (21/21) and MN1(high)/MN1(low) (21/22) groups, we detected that BAALC(high)/or MN1(high) patients had a tendency toward lower complete remission rate. Also, survival analysis showed that BAALC(high)/or MN1(high) patients had shorter disease-free survival and overall survival (OS). The most pronounced influence on prognosis was detected in FLT3-ITD-/NPM1(-) group of patients that are lacking reliable prognostic markers, where OS in BAALC(high)/or MN1(high) was only 5 months vs 25 months in BAALC(low)/or MN1(low). Conclusion These findings indicate that BAALC and MN1 expression level could be used for more precise risk stratification of AML-NK patients and especially FLT3-ITD-/NPM1(-) patients, transforming this intermediate-risk group, into a group with an adverse prognosis.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Laboratory Hematology",
title = "Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype",
pages = "440-433",
number = "3",
volume = "43",
doi = "10.1111/ijlh.13405"
}

Marjanović, I., Karan-Đurašević, T., Kostić, T., Virijević, M., Suvajdžić-Vuković, N., Pavlović, S.,& Tošić, N.. (2021). Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype. in International Journal of Laboratory Hematology
Wiley, Hoboken., 43(3), 433-440.
https://doi.org/10.1111/ijlh.13405

Marjanović I, Karan-Đurašević T, Kostić T, Virijević M, Suvajdžić-Vuković N, Pavlović S, Tošić N. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype. in International Journal of Laboratory Hematology. 2021;43(3):433-440.
doi:10.1111/ijlh.13405 .

Marjanović, Irena, Karan-Đurašević, Teodora, Kostić, Tatjana, Virijević, Marijana, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Tošić, Nataša, "Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype" in International Journal of Laboratory Hematology, 43, no. 3 (2021):433-440,
https://doi.org/10.1111/ijlh.13405 . .

TY  - JOUR
AU  - Janić, Dragana
AU  - Perić, Jelena
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Tatjana
AU  - Marjanović, Irena
AU  - Stanić, Bojana
AU  - Pejanović, Nadja
AU  - Dokmanović, Lidija
AU  - Lazić, Jelena
AU  - Krstovski, Nada
AU  - Virijević, Marijana
AU  - Tomin, Dragica
AU  - Vidović, Ana
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1303
AB  - lt b gt Uvod: lt /b gt  Akutna limfoblastna leukemija (ALL) je najčešće maligno oboljenje kod dece, dok je kod odraslih njena učestalost mnogo niža. U današnjoj kliničkoj praksi kao najvažnije metode stratifikacije pacijenata u određene grupe rizika koriste se metode identifikacije citogenetičkih aberacija i malog broja molekulanih markera. Tehnologija sekvenciranja nove generacije (SNG) obezbeđuje veliku količinu podataka koji doprinose razjašnjavanju mutacionog profila dečje (dALL) i adultne ALL (aALL).  lt b gt Metode: lt /b gt  Uzorci DNK iz 34 dALL i aALL pacijenata analizirani su primenom SNG ciljanog sekvenciranja ("TruSeq Amplicon Cancer Panel - TSACP") kojim se sekvenciraju "hotspot" mutacije u 48 gena povezanih sa kancerom.  lt b gt Rezultati: lt /b gt  Identifikovano je ukupno 330 varijanti u kodirajućim regionima, od kojih je samo 95 njih za posledicu imalo potencijalnu promenu u proteinu. Posmatrano kod pojedinačnih pacijenata, detektovane mutacije su pretežno remetile Ras/RTK signalni put (STK11, KIT, MET, NRAS, KRAS, PTEN). Pored toga, identifikovano je 5 pacijenata sa istom mutacijom u HNF1A genu, koja je uzrokovala poremećaje u Wnt i Notch signalnom putu. Kod dva pa cijenta otkrivene su varijante u NOTCH1 genu. Nije detektovano istovremeno prisustvo varijanti u HNF1A i NOTCH1 genu, dok su geni uključeni u Ras/RTK signalni put pokazali tendenciju ka akumuliranju mutacija.  lt b gt Zaključak: lt /b gt  Naši rezultati pokazuju da ALL sadrži Mali broj mutacija, bez značajnih razlika između dALL i aALL (medijana po pacijentu 2 odnosno 3). Detektovane mutacije izazivaju poremećaje u nekoliko ključnih signalnih puteva, prvenstveno Ras/RTK kaskade. Ova studija doprinosi ukupnom znanju o mutacionom profilu ALL, što vodi ka boljem razumijevanju molekularne osnove ovog oboljenja.
AB  - lt b gt Background: lt /b gt  Acute lymphoblastic leukemia (ALL) is the most common cancer in children, whereas it is less common in adults. Identification of cytogenetic aberrations and a small number of molecular abnormalities are still the most important risk and therapy stratification methods in clinical practice today. Next generation sequencing (NGS) technology provides a large amount of data contributing to elucidation of mutational landscape of childhood (cALL) and adult ALL (aALL).  lt b gt Methods: lt /b gt  We analyzed DNA samples from 34 cALL and aALL patients, using NGS targeted sequencing TruSeq Amplicon - Cancer Panel (TSACP) which targets mutational hotspots in 48 cancer related genes.  lt b gt Results: lt /b gt  We identified a total of 330 variants in the coding regions, out of which only 95 were potentially protein-changing. Observed in individual patients, detected mutations predominantly disrupted Ras/RTK pathway (STK11, KIT, MET, NRAS, KRAS, PTEN). Additionally, we identified 5 patients with the same mutation in HNF1A gene, disrupting both Wnt and Notch signaling pathway. In two patients we detected variants in NOTCH1 gene. HNF1A and NOTCH1 variants were mutually exclusive, while genes involved in Ras/RTK pathway exhibit a tendency of mutation accumulation.  lt b gt Conclusions: lt /b gt  Our results showed that ALL contains low number of mutations, without significant differences between cALL and aALL (median per patient 2 and 3, respectively). Detected mutations affect few key signaling pathways, primarily Ras/RTK cascade. This study contributes to knowledge of ALL mutational landscape, leading to better understanding of molecular basis of this disease.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Primena ciljanog sekvenciranja nove generacije u analizi mutacionog profila pacijenata sa akutnom limfoblastnom leukemijom
T1  - Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia
EP  - 82
IS  - 1
SP  - 72
VL  - 39
DO  - 10.2478/jomb-2019-0017
ER  - 

@article{
author = "Janić, Dragana and Perić, Jelena and Karan-Đurašević, Teodora and Kostić, Tatjana and Marjanović, Irena and Stanić, Bojana and Pejanović, Nadja and Dokmanović, Lidija and Lazić, Jelena and Krstovski, Nada and Virijević, Marijana and Tomin, Dragica and Vidović, Ana and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Tošić, Nataša",
year = "2020",
abstract = "lt b gt Uvod: lt /b gt  Akutna limfoblastna leukemija (ALL) je najčešće maligno oboljenje kod dece, dok je kod odraslih njena učestalost mnogo niža. U današnjoj kliničkoj praksi kao najvažnije metode stratifikacije pacijenata u određene grupe rizika koriste se metode identifikacije citogenetičkih aberacija i malog broja molekulanih markera. Tehnologija sekvenciranja nove generacije (SNG) obezbeđuje veliku količinu podataka koji doprinose razjašnjavanju mutacionog profila dečje (dALL) i adultne ALL (aALL).  lt b gt Metode: lt /b gt  Uzorci DNK iz 34 dALL i aALL pacijenata analizirani su primenom SNG ciljanog sekvenciranja ("TruSeq Amplicon Cancer Panel - TSACP") kojim se sekvenciraju "hotspot" mutacije u 48 gena povezanih sa kancerom.  lt b gt Rezultati: lt /b gt  Identifikovano je ukupno 330 varijanti u kodirajućim regionima, od kojih je samo 95 njih za posledicu imalo potencijalnu promenu u proteinu. Posmatrano kod pojedinačnih pacijenata, detektovane mutacije su pretežno remetile Ras/RTK signalni put (STK11, KIT, MET, NRAS, KRAS, PTEN). Pored toga, identifikovano je 5 pacijenata sa istom mutacijom u HNF1A genu, koja je uzrokovala poremećaje u Wnt i Notch signalnom putu. Kod dva pa cijenta otkrivene su varijante u NOTCH1 genu. Nije detektovano istovremeno prisustvo varijanti u HNF1A i NOTCH1 genu, dok su geni uključeni u Ras/RTK signalni put pokazali tendenciju ka akumuliranju mutacija.  lt b gt Zaključak: lt /b gt  Naši rezultati pokazuju da ALL sadrži Mali broj mutacija, bez značajnih razlika između dALL i aALL (medijana po pacijentu 2 odnosno 3). Detektovane mutacije izazivaju poremećaje u nekoliko ključnih signalnih puteva, prvenstveno Ras/RTK kaskade. Ova studija doprinosi ukupnom znanju o mutacionom profilu ALL, što vodi ka boljem razumijevanju molekularne osnove ovog oboljenja., lt b gt Background: lt /b gt  Acute lymphoblastic leukemia (ALL) is the most common cancer in children, whereas it is less common in adults. Identification of cytogenetic aberrations and a small number of molecular abnormalities are still the most important risk and therapy stratification methods in clinical practice today. Next generation sequencing (NGS) technology provides a large amount of data contributing to elucidation of mutational landscape of childhood (cALL) and adult ALL (aALL).  lt b gt Methods: lt /b gt  We analyzed DNA samples from 34 cALL and aALL patients, using NGS targeted sequencing TruSeq Amplicon - Cancer Panel (TSACP) which targets mutational hotspots in 48 cancer related genes.  lt b gt Results: lt /b gt  We identified a total of 330 variants in the coding regions, out of which only 95 were potentially protein-changing. Observed in individual patients, detected mutations predominantly disrupted Ras/RTK pathway (STK11, KIT, MET, NRAS, KRAS, PTEN). Additionally, we identified 5 patients with the same mutation in HNF1A gene, disrupting both Wnt and Notch signaling pathway. In two patients we detected variants in NOTCH1 gene. HNF1A and NOTCH1 variants were mutually exclusive, while genes involved in Ras/RTK pathway exhibit a tendency of mutation accumulation.  lt b gt Conclusions: lt /b gt  Our results showed that ALL contains low number of mutations, without significant differences between cALL and aALL (median per patient 2 and 3, respectively). Detected mutations affect few key signaling pathways, primarily Ras/RTK cascade. This study contributes to knowledge of ALL mutational landscape, leading to better understanding of molecular basis of this disease.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Primena ciljanog sekvenciranja nove generacije u analizi mutacionog profila pacijenata sa akutnom limfoblastnom leukemijom, Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia",
pages = "82-72",
number = "1",
volume = "39",
doi = "10.2478/jomb-2019-0017"
}

Janić, D., Perić, J., Karan-Đurašević, T., Kostić, T., Marjanović, I., Stanić, B., Pejanović, N., Dokmanović, L., Lazić, J., Krstovski, N., Virijević, M., Tomin, D., Vidović, A., Suvajdžić-Vuković, N., Pavlović, S.,& Tošić, N.. (2020). Primena ciljanog sekvenciranja nove generacije u analizi mutacionog profila pacijenata sa akutnom limfoblastnom leukemijom. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 39(1), 72-82.
https://doi.org/10.2478/jomb-2019-0017

Janić D, Perić J, Karan-Đurašević T, Kostić T, Marjanović I, Stanić B, Pejanović N, Dokmanović L, Lazić J, Krstovski N, Virijević M, Tomin D, Vidović A, Suvajdžić-Vuković N, Pavlović S, Tošić N. Primena ciljanog sekvenciranja nove generacije u analizi mutacionog profila pacijenata sa akutnom limfoblastnom leukemijom. in Journal of Medical Biochemistry. 2020;39(1):72-82.
doi:10.2478/jomb-2019-0017 .

Janić, Dragana, Perić, Jelena, Karan-Đurašević, Teodora, Kostić, Tatjana, Marjanović, Irena, Stanić, Bojana, Pejanović, Nadja, Dokmanović, Lidija, Lazić, Jelena, Krstovski, Nada, Virijević, Marijana, Tomin, Dragica, Vidović, Ana, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Tošić, Nataša, "Primena ciljanog sekvenciranja nove generacije u analizi mutacionog profila pacijenata sa akutnom limfoblastnom leukemijom" in Journal of Medical Biochemistry, 39, no. 1 (2020):72-82,
https://doi.org/10.2478/jomb-2019-0017 . .

TY  - JOUR
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Tatjana
AU  - Virijević, Marijana
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1391
AB  - According to current criteria, patients with acute myeloid leukemia with normal karyotype (AML-NK) are classified as intermediate risk patients. There is a constant need for additional molecular markers that will help in substratification into more precise prognostic groups. One of the potential new markers is Ecotropic viral integration 1 site (EVI1) transcriptional factor, whose expression is dissregulated in abnormal hematopoietic process. The purpose of this study was to examine EVI1 gene expression in 104 adult AML-NK patients and on 10 healthy bone marrow donors using real-time polymerase chain reaction method, and to evaluate association between EVI1 expression level and other molecular and clinical features, and to examine its potential influence on the prognosis of the disease. Overexpression of EVI1 gene (EVI1(+) status) was present in 17% of patients. Increased EVI1 expression was predominantly found in patients with lower WBC count (P = 0.003) and lower bone marrow blast percentage (P = 0.005). EVI1(+) patients had lower WT1 expression level (P = 0.041), and were negative for FLT3-ITD and NPM1 mutations (P = 0.036 and P = 0.003). Patients with EVI1(+) status had higher complete remission rate (P = 0.047), but EVI1 expression didn't influence overall and disease free survival. EVI1 expression status alone, cannot be used as a new marker for more precise substratification of AML-NK patients. Further investigations conducted on larger number of patients may indicate how EVI1 expression could influence the prognosis and outcome of AML-NK patients, by itself, or in the context of other molecular and clinical parameters.
PB  - Springer India, New Delhi
T2  - Indian Journal of Hematology and Blood Transfusion
T1  - Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype
EP  - 299
IS  - 2
SP  - 292
VL  - 36
DO  - 10.1007/s12288-019-01227-1
ER  - 

@article{
author = "Marjanović, Irena and Karan-Đurašević, Teodora and Kostić, Tatjana and Virijević, Marijana and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Tošić, Nataša",
year = "2020",
abstract = "According to current criteria, patients with acute myeloid leukemia with normal karyotype (AML-NK) are classified as intermediate risk patients. There is a constant need for additional molecular markers that will help in substratification into more precise prognostic groups. One of the potential new markers is Ecotropic viral integration 1 site (EVI1) transcriptional factor, whose expression is dissregulated in abnormal hematopoietic process. The purpose of this study was to examine EVI1 gene expression in 104 adult AML-NK patients and on 10 healthy bone marrow donors using real-time polymerase chain reaction method, and to evaluate association between EVI1 expression level and other molecular and clinical features, and to examine its potential influence on the prognosis of the disease. Overexpression of EVI1 gene (EVI1(+) status) was present in 17% of patients. Increased EVI1 expression was predominantly found in patients with lower WBC count (P = 0.003) and lower bone marrow blast percentage (P = 0.005). EVI1(+) patients had lower WT1 expression level (P = 0.041), and were negative for FLT3-ITD and NPM1 mutations (P = 0.036 and P = 0.003). Patients with EVI1(+) status had higher complete remission rate (P = 0.047), but EVI1 expression didn't influence overall and disease free survival. EVI1 expression status alone, cannot be used as a new marker for more precise substratification of AML-NK patients. Further investigations conducted on larger number of patients may indicate how EVI1 expression could influence the prognosis and outcome of AML-NK patients, by itself, or in the context of other molecular and clinical parameters.",
publisher = "Springer India, New Delhi",
journal = "Indian Journal of Hematology and Blood Transfusion",
title = "Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype",
pages = "299-292",
number = "2",
volume = "36",
doi = "10.1007/s12288-019-01227-1"
}

Marjanović, I., Karan-Đurašević, T., Kostić, T., Virijević, M., Suvajdžić-Vuković, N., Pavlović, S.,& Tošić, N.. (2020). Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype. in Indian Journal of Hematology and Blood Transfusion
Springer India, New Delhi., 36(2), 292-299.
https://doi.org/10.1007/s12288-019-01227-1

Marjanović I, Karan-Đurašević T, Kostić T, Virijević M, Suvajdžić-Vuković N, Pavlović S, Tošić N. Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype. in Indian Journal of Hematology and Blood Transfusion. 2020;36(2):292-299.
doi:10.1007/s12288-019-01227-1 .

Marjanović, Irena, Karan-Đurašević, Teodora, Kostić, Tatjana, Virijević, Marijana, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Tošić, Nataša, "Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype" in Indian Journal of Hematology and Blood Transfusion, 36, no. 2 (2020):292-299,
https://doi.org/10.1007/s12288-019-01227-1 . .

TY  - JOUR
AU  - Mitrović, Mirjana
AU  - Kostić, Tatjana
AU  - Virijević, Marijana
AU  - Karan-Đurašević, Teodora
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1403
AB  - Introduction Patients with acute promyelocytic leukemia (APL) are characterized by the highest expression of Wilms' tumor 1 (WT1) gene compared with other subtypes of acute myeloid leukemia, and yet this molecular marker is almost never used for risk stratification and in therapy response monitoring. Methods Quantitative assessment of Wilms' tumor 1 (WT1) gene transcripts was performed using real-time PCR method. The bone marrow samples were collected at the time of diagnosis for 47 APL patients, and for 31/47 patients during follow-up/relapse of the disease (129 samples in total). We examined how this molecular marker can be used for prognosis and minimal residual disease (MRD) monitoring. Results Increased WT1 expression was found in 34% of patients. WT1(high) status was an independent unfavorable factor for early death occurrence and was associated with shorter overall survival (OS). Assessment of log reduction value of WT1 expression in paired diagnosis/complete remission samples did not reveal its impact on relapse rate, disease-free survival, and OS. Also, measurement of WT1 expression level at different time points during therapy was not a reliable method for MRD monitoring. Conclusion Increased expression of WT1 gene detected in high proportion of APL patients could be considered as a marker for more precise risk stratification models in an attempt to further improve treatment and outcome of APL patients.
PB  - Wiley, Hoboken
T2  - International Journal of Laboratory Hematology
T1  - The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients
EP  - 87
IS  - 1
SP  - 82
VL  - 42
DO  - 10.1111/ijlh.13144
ER  - 

@article{
author = "Mitrović, Mirjana and Kostić, Tatjana and Virijević, Marijana and Karan-Đurašević, Teodora and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Tošić, Nataša",
year = "2020",
abstract = "Introduction Patients with acute promyelocytic leukemia (APL) are characterized by the highest expression of Wilms' tumor 1 (WT1) gene compared with other subtypes of acute myeloid leukemia, and yet this molecular marker is almost never used for risk stratification and in therapy response monitoring. Methods Quantitative assessment of Wilms' tumor 1 (WT1) gene transcripts was performed using real-time PCR method. The bone marrow samples were collected at the time of diagnosis for 47 APL patients, and for 31/47 patients during follow-up/relapse of the disease (129 samples in total). We examined how this molecular marker can be used for prognosis and minimal residual disease (MRD) monitoring. Results Increased WT1 expression was found in 34% of patients. WT1(high) status was an independent unfavorable factor for early death occurrence and was associated with shorter overall survival (OS). Assessment of log reduction value of WT1 expression in paired diagnosis/complete remission samples did not reveal its impact on relapse rate, disease-free survival, and OS. Also, measurement of WT1 expression level at different time points during therapy was not a reliable method for MRD monitoring. Conclusion Increased expression of WT1 gene detected in high proportion of APL patients could be considered as a marker for more precise risk stratification models in an attempt to further improve treatment and outcome of APL patients.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Laboratory Hematology",
title = "The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients",
pages = "87-82",
number = "1",
volume = "42",
doi = "10.1111/ijlh.13144"
}

Mitrović, M., Kostić, T., Virijević, M., Karan-Đurašević, T., Suvajdžić-Vuković, N., Pavlović, S.,& Tošić, N.. (2020). The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. in International Journal of Laboratory Hematology
Wiley, Hoboken., 42(1), 82-87.
https://doi.org/10.1111/ijlh.13144

Mitrović M, Kostić T, Virijević M, Karan-Đurašević T, Suvajdžić-Vuković N, Pavlović S, Tošić N. The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. in International Journal of Laboratory Hematology. 2020;42(1):82-87.
doi:10.1111/ijlh.13144 .

Mitrović, Mirjana, Kostić, Tatjana, Virijević, Marijana, Karan-Đurašević, Teodora, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Tošić, Nataša, "The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients" in International Journal of Laboratory Hematology, 42, no. 1 (2020):82-87,
https://doi.org/10.1111/ijlh.13144 . .

TY  - JOUR
AU  - Rodić, Predrag
AU  - Lakočević, Milan
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Tatjana
AU  - Suvajdžić-Vuković, Nada
AU  - Šumarac, Zorica
AU  - Petakov, Milan
AU  - Janić, Dragana
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1113
AB  - Uvod: Nekoliko studija u literaturi navode dokaze o povećanoj incidenci hematoloških komplikacija u bolesnika sa Gošeovom bolešću, uključujući monoklonsku i poliklonsku gamapatiju i hematološke malignitete, a posebno multipli mijelom. Metode: Određivana je serumska koncentracija imunoglobulina kao i rearanžman gena za teški lanac imunoglobulina - IGH, PCR analizom. Klonalni PCR produkti su direktno sekvencirani i analizirani koristeći adekvatne alate i baze podataka. Monoklonski proteini seruma su detektovani i identifikovani metodom elektroforeze. Rezultati: Među 27 bolesnika, klonalni IGH rearanžman je otkriven kod osmoro, od kojih je petoro imalo i monot klonski protein u serumu. Hipergamaglobulinemija je otkrivena u 9/27 bolesnika. Podaci o praćenju za 17 bolesnika su pokazali da je klonalni rearanžman ostao isti u četiri bolesnika, dok je u jednog bolesnika iščezao tokom perioda praćenja. Preostalih 12/17 bolesnika nisu imali klonalni IGH rearanžman niti su ga stekli nakon perioda praćenja. Zaključak: Iako klonska ekspanzija može da nastane relativno rano u toku Gošeove bolesti, barem sudeći prema rearanžmanu IGH gena, detektovani klonovi mogu biti tranzitorni. Pažljivo kliničko praćenje ovih bolesnika je obavezno, uključujući i nadzor nad limfoidnim neoplazmama, posebno multiplim mijelomom.
AB  - Background: Several studies support the evidence of increased incidence of hematological complications in Gaucher disease including monoclonal and polyclonal gammopathies and blood malignancies, especially multiple myeloma. Methods: Serum concentrations of immunoglobulins and PCR analysis of the IGH gene rearrangements were performed. The clonal PCR products were directly sequenced and analyzed with the appropriate database and tools. Serum monoclonal proteins were detected and identified by electrophoresis. Results: Among 27 Gaucher patients, clonal IGH rearrangement was discovered in eight, with 5/8 having also serum monoclonal protein. Elevated immunoglobulins were detected in 9/27 patients. Follow-up data for 17 patients showed that the clonal rearrangement remained the same in four of them, however, in one patient it disappeared after the follow-up period. The remaining 12/17 patients were without previous IGH clonal rearrangement and remained so after the follow-up. Conclusions: Although clonal expansion may occur relatively early in the disease course, at least judging by the IGH gene rearrangements in Gaucher patients, the detected clones may be transient. A careful clinical follow-up in these patients is mandatory, including monitoring for lymphoid neoplasms, especially multiple myeloma.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Rearanžmani gena za teški lanac imunoglobulina u bolesnika sa Gošeovom bolešću
T1  - Immunoglobulin heavy chain gene rearrangements in patients with Gaucher disease
EP  - 312
IS  - 3
SP  - 307
VL  - 37
DO  - 10.1515/jomb-2017-0061
ER  - 

@article{
author = "Rodić, Predrag and Lakočević, Milan and Pavlović, Sonja and Karan-Đurašević, Teodora and Kostić, Tatjana and Suvajdžić-Vuković, Nada and Šumarac, Zorica and Petakov, Milan and Janić, Dragana",
year = "2018",
abstract = "Uvod: Nekoliko studija u literaturi navode dokaze o povećanoj incidenci hematoloških komplikacija u bolesnika sa Gošeovom bolešću, uključujući monoklonsku i poliklonsku gamapatiju i hematološke malignitete, a posebno multipli mijelom. Metode: Određivana je serumska koncentracija imunoglobulina kao i rearanžman gena za teški lanac imunoglobulina - IGH, PCR analizom. Klonalni PCR produkti su direktno sekvencirani i analizirani koristeći adekvatne alate i baze podataka. Monoklonski proteini seruma su detektovani i identifikovani metodom elektroforeze. Rezultati: Među 27 bolesnika, klonalni IGH rearanžman je otkriven kod osmoro, od kojih je petoro imalo i monot klonski protein u serumu. Hipergamaglobulinemija je otkrivena u 9/27 bolesnika. Podaci o praćenju za 17 bolesnika su pokazali da je klonalni rearanžman ostao isti u četiri bolesnika, dok je u jednog bolesnika iščezao tokom perioda praćenja. Preostalih 12/17 bolesnika nisu imali klonalni IGH rearanžman niti su ga stekli nakon perioda praćenja. Zaključak: Iako klonska ekspanzija može da nastane relativno rano u toku Gošeove bolesti, barem sudeći prema rearanžmanu IGH gena, detektovani klonovi mogu biti tranzitorni. Pažljivo kliničko praćenje ovih bolesnika je obavezno, uključujući i nadzor nad limfoidnim neoplazmama, posebno multiplim mijelomom., Background: Several studies support the evidence of increased incidence of hematological complications in Gaucher disease including monoclonal and polyclonal gammopathies and blood malignancies, especially multiple myeloma. Methods: Serum concentrations of immunoglobulins and PCR analysis of the IGH gene rearrangements were performed. The clonal PCR products were directly sequenced and analyzed with the appropriate database and tools. Serum monoclonal proteins were detected and identified by electrophoresis. Results: Among 27 Gaucher patients, clonal IGH rearrangement was discovered in eight, with 5/8 having also serum monoclonal protein. Elevated immunoglobulins were detected in 9/27 patients. Follow-up data for 17 patients showed that the clonal rearrangement remained the same in four of them, however, in one patient it disappeared after the follow-up period. The remaining 12/17 patients were without previous IGH clonal rearrangement and remained so after the follow-up. Conclusions: Although clonal expansion may occur relatively early in the disease course, at least judging by the IGH gene rearrangements in Gaucher patients, the detected clones may be transient. A careful clinical follow-up in these patients is mandatory, including monitoring for lymphoid neoplasms, especially multiple myeloma.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Rearanžmani gena za teški lanac imunoglobulina u bolesnika sa Gošeovom bolešću, Immunoglobulin heavy chain gene rearrangements in patients with Gaucher disease",
pages = "312-307",
number = "3",
volume = "37",
doi = "10.1515/jomb-2017-0061"
}

Rodić, P., Lakočević, M., Pavlović, S., Karan-Đurašević, T., Kostić, T., Suvajdžić-Vuković, N., Šumarac, Z., Petakov, M.,& Janić, D.. (2018). Rearanžmani gena za teški lanac imunoglobulina u bolesnika sa Gošeovom bolešću. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 37(3), 307-312.
https://doi.org/10.1515/jomb-2017-0061

Rodić P, Lakočević M, Pavlović S, Karan-Đurašević T, Kostić T, Suvajdžić-Vuković N, Šumarac Z, Petakov M, Janić D. Rearanžmani gena za teški lanac imunoglobulina u bolesnika sa Gošeovom bolešću. in Journal of Medical Biochemistry. 2018;37(3):307-312.
doi:10.1515/jomb-2017-0061 .

Rodić, Predrag, Lakočević, Milan, Pavlović, Sonja, Karan-Đurašević, Teodora, Kostić, Tatjana, Suvajdžić-Vuković, Nada, Šumarac, Zorica, Petakov, Milan, Janić, Dragana, "Rearanžmani gena za teški lanac imunoglobulina u bolesnika sa Gošeovom bolešću" in Journal of Medical Biochemistry, 37, no. 3 (2018):307-312,
https://doi.org/10.1515/jomb-2017-0061 . .

TY  - JOUR
AU  - Tošić, Nataša
AU  - Petrović, Isidora
AU  - Kovačević Grujičić, Nataša
AU  - Davidović, Slobodan
AU  - Virijević, Marijana
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Stevanović, Milena
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1196
AB  - Aberrant expression of different SOX (SRY-related high mobility group (HMG) box) genes has been observed in number of tumors but, little is known about their expression patterns in hematological malignancies, especially in acute myeloid leukemia (AML). In this study we investigated SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in 50 de novo adult AML patients and correlated our findings with known clinical and molecular prognostic markers of the disease. We have found that these genes are overexpressed in 10-22% of patients and preliminary findings suggest that high expression level of these genes may have prognostic significance in AML patients. This is the first study focused on examining the expression level of SOX2, SOX3, SOX11, SOX14 and SOX18 genes in AML patients. Although this is a relatively limited study, initial findings indicate the need for further investigation of these genes, their potential roles in leukemia pathogenesis as well as prognosis in AML patients.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Leukemia Research
T1  - Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia
EP  - 38
SP  - 32
VL  - 67
DO  - 10.1016/j.leukres.2018.02.001
ER  - 

@article{
author = "Tošić, Nataša and Petrović, Isidora and Kovačević Grujičić, Nataša and Davidović, Slobodan and Virijević, Marijana and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Stevanović, Milena",
year = "2018",
abstract = "Aberrant expression of different SOX (SRY-related high mobility group (HMG) box) genes has been observed in number of tumors but, little is known about their expression patterns in hematological malignancies, especially in acute myeloid leukemia (AML). In this study we investigated SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in 50 de novo adult AML patients and correlated our findings with known clinical and molecular prognostic markers of the disease. We have found that these genes are overexpressed in 10-22% of patients and preliminary findings suggest that high expression level of these genes may have prognostic significance in AML patients. This is the first study focused on examining the expression level of SOX2, SOX3, SOX11, SOX14 and SOX18 genes in AML patients. Although this is a relatively limited study, initial findings indicate the need for further investigation of these genes, their potential roles in leukemia pathogenesis as well as prognosis in AML patients.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Leukemia Research",
title = "Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia",
pages = "38-32",
volume = "67",
doi = "10.1016/j.leukres.2018.02.001"
}

Tošić, N., Petrović, I., Kovačević Grujičić, N., Davidović, S., Virijević, M., Suvajdžić-Vuković, N., Pavlović, S.,& Stevanović, M.. (2018). Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia. in Leukemia Research
Pergamon-Elsevier Science Ltd, Oxford., 67, 32-38.
https://doi.org/10.1016/j.leukres.2018.02.001

Tošić N, Petrović I, Kovačević Grujičić N, Davidović S, Virijević M, Suvajdžić-Vuković N, Pavlović S, Stevanović M. Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia. in Leukemia Research. 2018;67:32-38.
doi:10.1016/j.leukres.2018.02.001 .

Tošić, Nataša, Petrović, Isidora, Kovačević Grujičić, Nataša, Davidović, Slobodan, Virijević, Marijana, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Stevanović, Milena, "Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia" in Leukemia Research, 67 (2018):32-38,
https://doi.org/10.1016/j.leukres.2018.02.001 . .

TY  - JOUR
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Ugrin, Milena
AU  - Virijević, Marijana
AU  - Vidović, Ana
AU  - Tomin, Dragica
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1089
AB  - The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpression of WT1 had a negative effect on treatment outcome. It was a suitable marker for MRD monitoring and a marker for refined risk stratification of AML-NK patients. Background: Acute myeloid leukemia with normal karyotype (AML-NK) represents the largest group of AML patients classified with an intermediate prognosis. A constant need exists to introduce new molecular markers for more precise risk stratification and for minimal residual disease (MRD) monitoring. Patients and Methods: Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts was performed using real-time polymerase chain reaction. The bone marrow samples were collected at the diagnosis from 104 AML-NK patients and from 34 of these patients during follow-up or disease relapse. Results: We found that overexpression of the WT1 gene (WT1(high) status), present in 25.5% of patients, was an independent unfavorable factor for achieving complete remission. WT1(high) status was also associated with resistance to therapy and shorter disease-free survival and overall survival. Assessment of the log reduction value of WT1 expression, measured in paired diagnosis/complete remission samples, revealed that patients with a log reduction of  lt  2 had a tendency toward shorter disease-free survival and overall survival and a greater incidence of disease relapse. Combining WT1 gene expression status with NPM1 and FLT3-ITD mutational status, we found that the tumor behavior of intermediate patients (FLT3(-)ITD-/NPM1(-) double negative) with WT1(high) status is almost the same as the tumor behavior of the adverse risk group. Conclusion: WT1 expression status represents a good molecular marker of prognosis, response to treatment, and MRD monitoring. Above all, the usage of the WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients could lead to more adapted, personalized treatment protocols.
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
EP  - 319
IS  - 5
SP  - 312
VL  - 17
DO  - 10.1016/j.clml.2016.12.006
ER  - 

@article{
author = "Marjanović, Irena and Karan-Đurašević, Teodora and Ugrin, Milena and Virijević, Marijana and Vidović, Ana and Tomin, Dragica and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Tošić, Nataša",
year = "2017",
abstract = "The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpression of WT1 had a negative effect on treatment outcome. It was a suitable marker for MRD monitoring and a marker for refined risk stratification of AML-NK patients. Background: Acute myeloid leukemia with normal karyotype (AML-NK) represents the largest group of AML patients classified with an intermediate prognosis. A constant need exists to introduce new molecular markers for more precise risk stratification and for minimal residual disease (MRD) monitoring. Patients and Methods: Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts was performed using real-time polymerase chain reaction. The bone marrow samples were collected at the diagnosis from 104 AML-NK patients and from 34 of these patients during follow-up or disease relapse. Results: We found that overexpression of the WT1 gene (WT1(high) status), present in 25.5% of patients, was an independent unfavorable factor for achieving complete remission. WT1(high) status was also associated with resistance to therapy and shorter disease-free survival and overall survival. Assessment of the log reduction value of WT1 expression, measured in paired diagnosis/complete remission samples, revealed that patients with a log reduction of  lt  2 had a tendency toward shorter disease-free survival and overall survival and a greater incidence of disease relapse. Combining WT1 gene expression status with NPM1 and FLT3-ITD mutational status, we found that the tumor behavior of intermediate patients (FLT3(-)ITD-/NPM1(-) double negative) with WT1(high) status is almost the same as the tumor behavior of the adverse risk group. Conclusion: WT1 expression status represents a good molecular marker of prognosis, response to treatment, and MRD monitoring. Above all, the usage of the WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients could lead to more adapted, personalized treatment protocols.",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients",
pages = "319-312",
number = "5",
volume = "17",
doi = "10.1016/j.clml.2016.12.006"
}

Marjanović, I., Karan-Đurašević, T., Ugrin, M., Virijević, M., Vidović, A., Tomin, D., Suvajdžić-Vuković, N., Pavlović, S.,& Tošić, N.. (2017). Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 17(5), 312-319.
https://doi.org/10.1016/j.clml.2016.12.006

Marjanović I, Karan-Đurašević T, Ugrin M, Virijević M, Vidović A, Tomin D, Suvajdžić-Vuković N, Pavlović S, Tošić N. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. in Clinical Lymphoma Myeloma & Leukemia. 2017;17(5):312-319.
doi:10.1016/j.clml.2016.12.006 .

Marjanović, Irena, Karan-Đurašević, Teodora, Ugrin, Milena, Virijević, Marijana, Vidović, Ana, Tomin, Dragica, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Tošić, Nataša, "Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients" in Clinical Lymphoma Myeloma & Leukemia, 17, no. 5 (2017):312-319,
https://doi.org/10.1016/j.clml.2016.12.006 . .

TY  - CONF
AU  - Perić, Jelena
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Tatjana 
AU  - Marjanović, Irena
AU  - Lazić, J.
AU  - Virijević, M.
AU  - Krstovski, N.
AU  - Dokmanović, Lidija
AU  - Tomin, D.
AU  - Vidović, A.
AU  - Suvajdžić-Vuković, Nada
AU  - Janić, D.
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1071
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients
EP  - 653
SP  - 653
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1071
ER  - 

@conference{
author = "Perić, Jelena and Karan-Đurašević, Teodora and Kostić, Tatjana  and Marjanović, Irena and Lazić, J. and Virijević, M. and Krstovski, N. and Dokmanović, Lidija and Tomin, D. and Vidović, A. and Suvajdžić-Vuković, Nada and Janić, D. and Pavlović, Sonja and Tošić, Nataša",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients",
pages = "653-653",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1071"
}

Perić, J., Karan-Đurašević, T., Kostić, T., Marjanović, I., Lazić, J., Virijević, M., Krstovski, N., Dokmanović, L., Tomin, D., Vidović, A., Suvajdžić-Vuković, N., Janić, D., Pavlović, S.,& Tošić, N.. (2017). Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 653-653.
https://hdl.handle.net/21.15107/rcub_imagine_1071

Perić J, Karan-Đurašević T, Kostić T, Marjanović I, Lazić J, Virijević M, Krstovski N, Dokmanović L, Tomin D, Vidović A, Suvajdžić-Vuković N, Janić D, Pavlović S, Tošić N. Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients. in Haematologica-The Hematology Journal. 2017;102:653-653.
https://hdl.handle.net/21.15107/rcub_imagine_1071 .

Perić, Jelena, Karan-Đurašević, Teodora, Kostić, Tatjana , Marjanović, Irena, Lazić, J., Virijević, M., Krstovski, N., Dokmanović, Lidija, Tomin, D., Vidović, A., Suvajdžić-Vuković, Nada, Janić, D., Pavlović, Sonja, Tošić, Nataša, "Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients" in Haematologica-The Hematology Journal, 102 (2017):653-653,
https://hdl.handle.net/21.15107/rcub_imagine_1071 .

TY  - CONF
AU  - Tošić, Nataša
AU  - Virijević, M.
AU  - Petrović, Isidora
AU  - Kovačević Grujičić, Nataša
AU  - Davidović, Slobodan
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Stevanović, Milena
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1073
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Prognostic significance of sox2, sox3, sox11, sox14 and sox18 gene expression in de novo acute myeloid leukemia (AML) patients
EP  - 390
SP  - 390
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1073
ER  - 

@conference{
author = "Tošić, Nataša and Virijević, M. and Petrović, Isidora and Kovačević Grujičić, Nataša and Davidović, Slobodan and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Stevanović, Milena",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Prognostic significance of sox2, sox3, sox11, sox14 and sox18 gene expression in de novo acute myeloid leukemia (AML) patients",
pages = "390-390",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1073"
}

Tošić, N., Virijević, M., Petrović, I., Kovačević Grujičić, N., Davidović, S., Suvajdžić-Vuković, N., Pavlović, S.,& Stevanović, M.. (2017). Prognostic significance of sox2, sox3, sox11, sox14 and sox18 gene expression in de novo acute myeloid leukemia (AML) patients. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 390-390.
https://hdl.handle.net/21.15107/rcub_imagine_1073

Tošić N, Virijević M, Petrović I, Kovačević Grujičić N, Davidović S, Suvajdžić-Vuković N, Pavlović S, Stevanović M. Prognostic significance of sox2, sox3, sox11, sox14 and sox18 gene expression in de novo acute myeloid leukemia (AML) patients. in Haematologica-The Hematology Journal. 2017;102:390-390.
https://hdl.handle.net/21.15107/rcub_imagine_1073 .

Tošić, Nataša, Virijević, M., Petrović, Isidora, Kovačević Grujičić, Nataša, Davidović, Slobodan, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Stevanović, Milena, "Prognostic significance of sox2, sox3, sox11, sox14 and sox18 gene expression in de novo acute myeloid leukemia (AML) patients" in Haematologica-The Hematology Journal, 102 (2017):390-390,
https://hdl.handle.net/21.15107/rcub_imagine_1073 .

TY  - JOUR
AU  - Marjanović, Irena
AU  - Perić, Jelena
AU  - Stanić, Bojana
AU  - Pejanović, Nadja
AU  - Lucić, Bojana
AU  - Karan-Đurašević, Teodora
AU  - Janić, Dragana
AU  - Dokmanović, Lidija
AU  - Janković, Srdja
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, Dragica
AU  - Perisić, Ognjen
AU  - Rakocević, Goran
AU  - Popović, Milos
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/932
AB  - The age-specific differences in the genetic mechanisms of myeloid leukemogenesis have been observed and studied previously. However, NGS technology has provided a possibility to obtain a large amount of mutation data. We analyzed DNA samples from 20 childhood (cAML) and 20 adult AML (aAML) patients, using NGS targeted sequencing. The average coverage of high-quality sequences was 2981 x per amplicon. A total of 412 (207 cAML, 205 aAML) variants in the coding regions were detected; out of which, only 122 (62 cAML and 60 aAML) were potentially protein-changing. Our results confirmed that AML contains small number of genetic alterations (median 3 mutations/patient in both groups). The prevalence of the most frequent single gene AML associated mutations differed in cAML and aAML patient cohorts: IDH1 (0 % cAML, 5 % aAML), IDH2 (0 % cAML, 10 % aAML), NPM1 (10 % cAML, 35 % aAML). Additionally, potentially protein-changing variants were found in tyrosine kinase genes or genes encoding tyrosine kinase associated proteins (JAK3, ABL1, GNAQ, and EGFR) in cAML, while among aAML, the prevalence is directed towards variants in the methylation and histone modifying genes (IDH1, IDH2, and SMARCB1). Besides uniform genomic profile of AML, specific genetic characteristic was exclusively detected in cAML and aAML.
PB  - Sage Publications Ltd, London
T2  - Tumor Biology
T1  - Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease
EP  - 13401
IS  - 10
SP  - 13391
VL  - 37
DO  - 10.1007/s13277-016-5142-7
ER  - 

@article{
author = "Marjanović, Irena and Perić, Jelena and Stanić, Bojana and Pejanović, Nadja and Lucić, Bojana and Karan-Đurašević, Teodora and Janić, Dragana and Dokmanović, Lidija and Janković, Srdja and Suvajdžić-Vuković, Nada and Tomin, Dragica and Perisić, Ognjen and Rakocević, Goran and Popović, Milos and Pavlović, Sonja and Tošić, Nataša",
year = "2016",
abstract = "The age-specific differences in the genetic mechanisms of myeloid leukemogenesis have been observed and studied previously. However, NGS technology has provided a possibility to obtain a large amount of mutation data. We analyzed DNA samples from 20 childhood (cAML) and 20 adult AML (aAML) patients, using NGS targeted sequencing. The average coverage of high-quality sequences was 2981 x per amplicon. A total of 412 (207 cAML, 205 aAML) variants in the coding regions were detected; out of which, only 122 (62 cAML and 60 aAML) were potentially protein-changing. Our results confirmed that AML contains small number of genetic alterations (median 3 mutations/patient in both groups). The prevalence of the most frequent single gene AML associated mutations differed in cAML and aAML patient cohorts: IDH1 (0 % cAML, 5 % aAML), IDH2 (0 % cAML, 10 % aAML), NPM1 (10 % cAML, 35 % aAML). Additionally, potentially protein-changing variants were found in tyrosine kinase genes or genes encoding tyrosine kinase associated proteins (JAK3, ABL1, GNAQ, and EGFR) in cAML, while among aAML, the prevalence is directed towards variants in the methylation and histone modifying genes (IDH1, IDH2, and SMARCB1). Besides uniform genomic profile of AML, specific genetic characteristic was exclusively detected in cAML and aAML.",
publisher = "Sage Publications Ltd, London",
journal = "Tumor Biology",
title = "Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease",
pages = "13401-13391",
number = "10",
volume = "37",
doi = "10.1007/s13277-016-5142-7"
}

Marjanović, I., Perić, J., Stanić, B., Pejanović, N., Lucić, B., Karan-Đurašević, T., Janić, D., Dokmanović, L., Janković, S., Suvajdžić-Vuković, N., Tomin, D., Perisić, O., Rakocević, G., Popović, M., Pavlović, S.,& Tošić, N.. (2016). Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease. in Tumor Biology
Sage Publications Ltd, London., 37(10), 13391-13401.
https://doi.org/10.1007/s13277-016-5142-7

Marjanović I, Perić J, Stanić B, Pejanović N, Lucić B, Karan-Đurašević T, Janić D, Dokmanović L, Janković S, Suvajdžić-Vuković N, Tomin D, Perisić O, Rakocević G, Popović M, Pavlović S, Tošić N. Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease. in Tumor Biology. 2016;37(10):13391-13401.
doi:10.1007/s13277-016-5142-7 .

Marjanović, Irena, Perić, Jelena, Stanić, Bojana, Pejanović, Nadja, Lucić, Bojana, Karan-Đurašević, Teodora, Janić, Dragana, Dokmanović, Lidija, Janković, Srdja, Suvajdžić-Vuković, Nada, Tomin, Dragica, Perisić, Ognjen, Rakocević, Goran, Popović, Milos, Pavlović, Sonja, Tošić, Nataša, "Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease" in Tumor Biology, 37, no. 10 (2016):13391-13401,
https://doi.org/10.1007/s13277-016-5142-7 . .

TY  - JOUR
AU  - Virijević, Marijana
AU  - Karan-Đurašević, Teodora
AU  - Marjanović, Irena
AU  - Tošić, Nataša
AU  - Mitrović, Mirjana
AU  - Djunić, Irena
AU  - Čolović, Nataša
AU  - Vidović, Ana
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, Dragica
AU  - Pavlović, Sonja
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/963
AB  - Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.
PB  - Walter De Gruyter Gmbh, Berlin
T2  - Radiology and Oncology
T1  - Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
EP  - 393
IS  - 4
SP  - 385
VL  - 50
DO  - 10.1515/raon-2016-0044
ER  - 

@article{
author = "Virijević, Marijana and Karan-Đurašević, Teodora and Marjanović, Irena and Tošić, Nataša and Mitrović, Mirjana and Djunić, Irena and Čolović, Nataša and Vidović, Ana and Suvajdžić-Vuković, Nada and Tomin, Dragica and Pavlović, Sonja",
year = "2016",
abstract = "Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.",
publisher = "Walter De Gruyter Gmbh, Berlin",
journal = "Radiology and Oncology",
title = "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype",
pages = "393-385",
number = "4",
volume = "50",
doi = "10.1515/raon-2016-0044"
}

Virijević, M., Karan-Đurašević, T., Marjanović, I., Tošić, N., Mitrović, M., Djunić, I., Čolović, N., Vidović, A., Suvajdžić-Vuković, N., Tomin, D.,& Pavlović, S.. (2016). Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology
Walter De Gruyter Gmbh, Berlin., 50(4), 385-393.
https://doi.org/10.1515/raon-2016-0044

Virijević M, Karan-Đurašević T, Marjanović I, Tošić N, Mitrović M, Djunić I, Čolović N, Vidović A, Suvajdžić-Vuković N, Tomin D, Pavlović S. Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology. 2016;50(4):385-393.
doi:10.1515/raon-2016-0044 .

Virijević, Marijana, Karan-Đurašević, Teodora, Marjanović, Irena, Tošić, Nataša, Mitrović, Mirjana, Djunić, Irena, Čolović, Nataša, Vidović, Ana, Suvajdžić-Vuković, Nada, Tomin, Dragica, Pavlović, Sonja, "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype" in Radiology and Oncology, 50, no. 4 (2016):385-393,
https://doi.org/10.1515/raon-2016-0044 . .

TY  - CONF
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Kostić, Jelena
AU  - Kostić, Tatjana 
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, D.
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/911
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Assessment of BAALC and MN1 gene expression level could contribute to improved prognostic stratification of the aml-nk patients
EP  - 382
SP  - 382
VL  - 101
UR  - https://hdl.handle.net/21.15107/rcub_imagine_911
ER  - 

@conference{
author = "Marjanović, Irena and Karan-Đurašević, Teodora and Kostić, Jelena and Kostić, Tatjana  and Virijević, M. and Djunić, I. and Suvajdžić-Vuković, Nada and Tomin, D. and Pavlović, Sonja and Tošić, Nataša",
year = "2016",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Assessment of BAALC and MN1 gene expression level could contribute to improved prognostic stratification of the aml-nk patients",
pages = "382-382",
volume = "101",
url = "https://hdl.handle.net/21.15107/rcub_imagine_911"
}

Marjanović, I., Karan-Đurašević, T., Kostić, J., Kostić, T., Virijević, M., Djunić, I., Suvajdžić-Vuković, N., Tomin, D., Pavlović, S.,& Tošić, N.. (2016). Assessment of BAALC and MN1 gene expression level could contribute to improved prognostic stratification of the aml-nk patients. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 101, 382-382.
https://hdl.handle.net/21.15107/rcub_imagine_911

Marjanović I, Karan-Đurašević T, Kostić J, Kostić T, Virijević M, Djunić I, Suvajdžić-Vuković N, Tomin D, Pavlović S, Tošić N. Assessment of BAALC and MN1 gene expression level could contribute to improved prognostic stratification of the aml-nk patients. in Haematologica-The Hematology Journal. 2016;101:382-382.
https://hdl.handle.net/21.15107/rcub_imagine_911 .

Marjanović, Irena, Karan-Đurašević, Teodora, Kostić, Jelena, Kostić, Tatjana , Virijević, M., Djunić, I., Suvajdžić-Vuković, Nada, Tomin, D., Pavlović, Sonja, Tošić, Nataša, "Assessment of BAALC and MN1 gene expression level could contribute to improved prognostic stratification of the aml-nk patients" in Haematologica-The Hematology Journal, 101 (2016):382-382,
https://hdl.handle.net/21.15107/rcub_imagine_911 .

TY  - JOUR
AU  - Mitrović, Mirjana
AU  - Suvajdžić, Nada
AU  - Elezović, Ivo
AU  - Bogdanović, Andrija
AU  - Đorđević, Valentina
AU  - Miljić, Predrag
AU  - Djunić, Irena
AU  - Gvozdenov, Maja
AU  - Čolović, Nataša
AU  - Virijević, Marijana
AU  - Leković, Danijela
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/891
AB  - Introduction: Thrombotic events (TE) appear to be more common in acute promyelocytic leukemia (APL) than in other acute leukemias, with reported prevalence ranging from 2 to 10-15%. Materials and Methods: We retrospectively analyzed the data on TE appearance in 63 APL patients. Results: TE occured in 13 (20.6%) cases, four arterial (6.3%) and nine venous (14.3%). TE were more frequently diagnosed after initiation of weekly D-dimer monitoring (7 TE during 20 months vs 6 during 76 months, P = 0.032). Patients with and without venous thrombosis were significantly different regarding female/male ratio (P = 0.046), PT (P = 0.022), a PTT (P = 0.044), ISTH DIC score (P = 0.001), bcr3 (P = 0.02) and FLT3-ITD (P = 0.028) mutation. The most significant risk factor for venous TE occurrence in multivariate analysis was FLT3-ITD mutation (P = 0.034). PAI-1 4G/4G polymorphism was five times more frequent in patients with venous TE than without it (P = 0.05). Regarding risk factors for arterial TE we failed to identify any. Conclusions: We have demonstrated that APL-related TE rate is higher than previously reported and that weekly D-dimer monitoring might help to identify patients with silent thrombosis. Moreover, our study suggests a possible relationship between venous TE occurrence and several laboratory findings (PT, aPTT, ISTH DIC score, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G). Prophylactic use of heparin might be considered in patients with ISTH DIC score  lt  5, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Thrombotic events in acute promyelocytic leukemia
EP  - 593
IS  - 4
SP  - 588
VL  - 135
DO  - 10.1016/j.thromres.2014.11.026
ER  - 

@article{
author = "Mitrović, Mirjana and Suvajdžić, Nada and Elezović, Ivo and Bogdanović, Andrija and Đorđević, Valentina and Miljić, Predrag and Djunić, Irena and Gvozdenov, Maja and Čolović, Nataša and Virijević, Marijana and Leković, Danijela and Vidović, Ana and Tomin, Dragica",
year = "2015",
abstract = "Introduction: Thrombotic events (TE) appear to be more common in acute promyelocytic leukemia (APL) than in other acute leukemias, with reported prevalence ranging from 2 to 10-15%. Materials and Methods: We retrospectively analyzed the data on TE appearance in 63 APL patients. Results: TE occured in 13 (20.6%) cases, four arterial (6.3%) and nine venous (14.3%). TE were more frequently diagnosed after initiation of weekly D-dimer monitoring (7 TE during 20 months vs 6 during 76 months, P = 0.032). Patients with and without venous thrombosis were significantly different regarding female/male ratio (P = 0.046), PT (P = 0.022), a PTT (P = 0.044), ISTH DIC score (P = 0.001), bcr3 (P = 0.02) and FLT3-ITD (P = 0.028) mutation. The most significant risk factor for venous TE occurrence in multivariate analysis was FLT3-ITD mutation (P = 0.034). PAI-1 4G/4G polymorphism was five times more frequent in patients with venous TE than without it (P = 0.05). Regarding risk factors for arterial TE we failed to identify any. Conclusions: We have demonstrated that APL-related TE rate is higher than previously reported and that weekly D-dimer monitoring might help to identify patients with silent thrombosis. Moreover, our study suggests a possible relationship between venous TE occurrence and several laboratory findings (PT, aPTT, ISTH DIC score, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G). Prophylactic use of heparin might be considered in patients with ISTH DIC score  lt  5, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Thrombotic events in acute promyelocytic leukemia",
pages = "593-588",
number = "4",
volume = "135",
doi = "10.1016/j.thromres.2014.11.026"
}

Mitrović, M., Suvajdžić, N., Elezović, I., Bogdanović, A., Đorđević, V., Miljić, P., Djunić, I., Gvozdenov, M., Čolović, N., Virijević, M., Leković, D., Vidović, A.,& Tomin, D.. (2015). Thrombotic events in acute promyelocytic leukemia. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 135(4), 588-593.
https://doi.org/10.1016/j.thromres.2014.11.026

Mitrović M, Suvajdžić N, Elezović I, Bogdanović A, Đorđević V, Miljić P, Djunić I, Gvozdenov M, Čolović N, Virijević M, Leković D, Vidović A, Tomin D. Thrombotic events in acute promyelocytic leukemia. in Thrombosis Research. 2015;135(4):588-593.
doi:10.1016/j.thromres.2014.11.026 .

Mitrović, Mirjana, Suvajdžić, Nada, Elezović, Ivo, Bogdanović, Andrija, Đorđević, Valentina, Miljić, Predrag, Djunić, Irena, Gvozdenov, Maja, Čolović, Nataša, Virijević, Marijana, Leković, Danijela, Vidović, Ana, Tomin, Dragica, "Thrombotic events in acute promyelocytic leukemia" in Thrombosis Research, 135, no. 4 (2015):588-593,
https://doi.org/10.1016/j.thromres.2014.11.026 . .

TY  - JOUR
AU  - Hackl, Hubert
AU  - Steinleitner, Katarina
AU  - Lind, Karin
AU  - Hofer, Sybille
AU  - Tošić, Nataša
AU  - Pavlović, Sonja
AU  - Suvajdžić, Nada
AU  - Sill, Heinz
AU  - Wieser, Rotraud
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/857
AB  - Some 50 – 80% of patients with acute myeloid leukemia (AML)
achieve a complete remission with contemporary chemotherapy protocols, yet the majority of them eventually relapse
with resistant disease: some patients no longer respond to
chemotherapy at disease recurrence; others accomplish
second and even third remissions whose decreasing duration nevertheless indicates that the pool of residual leukemic
cells, i.e. of cells that persisted during treatment with cytotoxic
drugs, increases with every round of therapy [1]. Either of
these clinical courses therefore refl ects an enhanced chemotherapy resistance of leukemic cells at relapse as compared to
the cell population at diagnosis. Molecular changes enabling
malignant cells to survive exposure to cytotoxic drugs may
already have been present in a subset of the leukemic cell
population at presentation, or may emerge during treatment
[2,3], but in any case are thought to be selected as a consequence of drug therapy, and to play a major role in therapy
resistance at relapse. Remarkably, however, even though
various types of molecular alterations may be acquired at
relapse, neither specifi c cytogenetic alterations nor functionally relevant point mutations as identifi ed by whole genome
sequencing were associated with relapse in a recurrent manner [2,3]. Certain copy number variations and known AML
associated point mutations were newly present at relapse in
small proportions of patients (usually  10%), but the latter
were lost in other patients, indicating that they are unlikely to
represent drivers of therapy resistance at disease recurrence
[4]. Th ese fi ndings could either indicate that chemotherapy
resistance at relapse is acquired through a large variety of different mechanisms, or that molecular changes of other types
than those mentioned above are of more general relevance
in this context. Indeed, an earlier study has suggested that
the expression of specifi c genes may change in a consistent
manner between diagnosis and relapse of AML [5]. However,
only a limited number of genes and mostly unpaired samples
were probed in this investigation. Th erefore, in the present
study, genes whose expression changed in a relapse-specifi c
manner were sought in a set of paired AML samples and on
a genome-wide scale. To limit the genetic heterogeneity of
the study population, only samples from patients with cytogenetically normal (CN) AML were used.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Leukemia & Lymphoma
T1  - A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes
EP  - 1128
IS  - 4
SP  - 1126
VL  - 56
DO  - 10.3109/10428194.2014.944523
ER  - 

@article{
author = "Hackl, Hubert and Steinleitner, Katarina and Lind, Karin and Hofer, Sybille and Tošić, Nataša and Pavlović, Sonja and Suvajdžić, Nada and Sill, Heinz and Wieser, Rotraud",
year = "2015",
abstract = "Some 50 – 80% of patients with acute myeloid leukemia (AML)
achieve a complete remission with contemporary chemotherapy protocols, yet the majority of them eventually relapse
with resistant disease: some patients no longer respond to
chemotherapy at disease recurrence; others accomplish
second and even third remissions whose decreasing duration nevertheless indicates that the pool of residual leukemic
cells, i.e. of cells that persisted during treatment with cytotoxic
drugs, increases with every round of therapy [1]. Either of
these clinical courses therefore refl ects an enhanced chemotherapy resistance of leukemic cells at relapse as compared to
the cell population at diagnosis. Molecular changes enabling
malignant cells to survive exposure to cytotoxic drugs may
already have been present in a subset of the leukemic cell
population at presentation, or may emerge during treatment
[2,3], but in any case are thought to be selected as a consequence of drug therapy, and to play a major role in therapy
resistance at relapse. Remarkably, however, even though
various types of molecular alterations may be acquired at
relapse, neither specifi c cytogenetic alterations nor functionally relevant point mutations as identifi ed by whole genome
sequencing were associated with relapse in a recurrent manner [2,3]. Certain copy number variations and known AML
associated point mutations were newly present at relapse in
small proportions of patients (usually  10%), but the latter
were lost in other patients, indicating that they are unlikely to
represent drivers of therapy resistance at disease recurrence
[4]. Th ese fi ndings could either indicate that chemotherapy
resistance at relapse is acquired through a large variety of different mechanisms, or that molecular changes of other types
than those mentioned above are of more general relevance
in this context. Indeed, an earlier study has suggested that
the expression of specifi c genes may change in a consistent
manner between diagnosis and relapse of AML [5]. However,
only a limited number of genes and mostly unpaired samples
were probed in this investigation. Th erefore, in the present
study, genes whose expression changed in a relapse-specifi c
manner were sought in a set of paired AML samples and on
a genome-wide scale. To limit the genetic heterogeneity of
the study population, only samples from patients with cytogenetically normal (CN) AML were used.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Leukemia & Lymphoma",
title = "A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes",
pages = "1128-1126",
number = "4",
volume = "56",
doi = "10.3109/10428194.2014.944523"
}

Hackl, H., Steinleitner, K., Lind, K., Hofer, S., Tošić, N., Pavlović, S., Suvajdžić, N., Sill, H.,& Wieser, R.. (2015). A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes. in Leukemia & Lymphoma
Taylor & Francis Ltd, Abingdon., 56(4), 1126-1128.
https://doi.org/10.3109/10428194.2014.944523

Hackl H, Steinleitner K, Lind K, Hofer S, Tošić N, Pavlović S, Suvajdžić N, Sill H, Wieser R. A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes. in Leukemia & Lymphoma. 2015;56(4):1126-1128.
doi:10.3109/10428194.2014.944523 .

Hackl, Hubert, Steinleitner, Katarina, Lind, Karin, Hofer, Sybille, Tošić, Nataša, Pavlović, Sonja, Suvajdžić, Nada, Sill, Heinz, Wieser, Rotraud, "A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes" in Leukemia & Lymphoma, 56, no. 4 (2015):1126-1128,
https://doi.org/10.3109/10428194.2014.944523 . .

TY  - CONF
AU  - Glumac, Irena
AU  - Kostić, Jelena
AU  - Stanić, B.
AU  - Pejanović, N.
AU  - Lucić, B.
AU  - Karan-Đurašević, Teodora
AU  - Janić, D.
AU  - Dokmanović, Lidija
AU  - Janković, S.
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, D.
AU  - Popović, M.
AU  - Bogicević, I.
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/824
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Targeted next generation sequencing (ngs) in parallel analyses of childhood (caml) and adult acute myeloid leukemia (AAML) patients
EP  - 360
SP  - 360
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_824
ER  - 

@conference{
author = "Glumac, Irena and Kostić, Jelena and Stanić, B. and Pejanović, N. and Lucić, B. and Karan-Đurašević, Teodora and Janić, D. and Dokmanović, Lidija and Janković, S. and Suvajdžić-Vuković, Nada and Tomin, D. and Popović, M. and Bogicević, I. and Pavlović, Sonja and Tošić, Nataša",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Targeted next generation sequencing (ngs) in parallel analyses of childhood (caml) and adult acute myeloid leukemia (AAML) patients",
pages = "360-360",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_824"
}

Glumac, I., Kostić, J., Stanić, B., Pejanović, N., Lucić, B., Karan-Đurašević, T., Janić, D., Dokmanović, L., Janković, S., Suvajdžić-Vuković, N., Tomin, D., Popović, M., Bogicević, I., Pavlović, S.,& Tošić, N.. (2015). Targeted next generation sequencing (ngs) in parallel analyses of childhood (caml) and adult acute myeloid leukemia (AAML) patients. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 360-360.
https://hdl.handle.net/21.15107/rcub_imagine_824

Glumac I, Kostić J, Stanić B, Pejanović N, Lucić B, Karan-Đurašević T, Janić D, Dokmanović L, Janković S, Suvajdžić-Vuković N, Tomin D, Popović M, Bogicević I, Pavlović S, Tošić N. Targeted next generation sequencing (ngs) in parallel analyses of childhood (caml) and adult acute myeloid leukemia (AAML) patients. in Haematologica-The Hematology Journal. 2015;100:360-360.
https://hdl.handle.net/21.15107/rcub_imagine_824 .

Glumac, Irena, Kostić, Jelena, Stanić, B., Pejanović, N., Lucić, B., Karan-Đurašević, Teodora, Janić, D., Dokmanović, Lidija, Janković, S., Suvajdžić-Vuković, Nada, Tomin, D., Popović, M., Bogicević, I., Pavlović, Sonja, Tošić, Nataša, "Targeted next generation sequencing (ngs) in parallel analyses of childhood (caml) and adult acute myeloid leukemia (AAML) patients" in Haematologica-The Hematology Journal, 100 (2015):360-360,
https://hdl.handle.net/21.15107/rcub_imagine_824 .

TY  - CONF
AU  - Mitrović, M.
AU  - Tošić, Nataša
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Čolović, Nataša
AU  - Glumac, Irena
AU  - Kostić, Tatjana 
AU  - Pavlović, Sonja
AU  - Elezović, I.
AU  - Tomin, D.
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/826
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia
EP  - 378
SP  - 377
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_826
ER  - 

@conference{
author = "Mitrović, M. and Tošić, Nataša and Suvajdžić, Nada and Djunić, I. and Vidović, A. and Virijević, M. and Čolović, Nataša and Glumac, Irena and Kostić, Tatjana  and Pavlović, Sonja and Elezović, I. and Tomin, D.",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia",
pages = "378-377",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_826"
}

Mitrović, M., Tošić, N., Suvajdžić, N., Djunić, I., Vidović, A., Virijević, M., Čolović, N., Glumac, I., Kostić, T., Pavlović, S., Elezović, I.,& Tomin, D.. (2015). Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 377-378.
https://hdl.handle.net/21.15107/rcub_imagine_826

Mitrović M, Tošić N, Suvajdžić N, Djunić I, Vidović A, Virijević M, Čolović N, Glumac I, Kostić T, Pavlović S, Elezović I, Tomin D. Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia. in Haematologica-The Hematology Journal. 2015;100:377-378.
https://hdl.handle.net/21.15107/rcub_imagine_826 .

Mitrović, M., Tošić, Nataša, Suvajdžić, Nada, Djunić, I., Vidović, A., Virijević, M., Čolović, Nataša, Glumac, Irena, Kostić, Tatjana , Pavlović, Sonja, Elezović, I., Tomin, D., "Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia" in Haematologica-The Hematology Journal, 100 (2015):377-378,
https://hdl.handle.net/21.15107/rcub_imagine_826 .

TY  - CONF
AU  - Pudja, A.
AU  - Milosević, J. D.
AU  - Klampfl, T.
AU  - Harutyunyan, A.
AU  - Berg, T.
AU  - Bagienski, K.
AU  - Chen, D.
AU  - Gisslinger, B.
AU  - Rumi, E.
AU  - Malcovati, L.
AU  - Pietra, Daniela
AU  - Elena, C.
AU  - Della Porta, M. G.
AU  - Pieri, Lisa
AU  - Guglielmelli, Paola
AU  - Doubek, M.
AU  - Dvorakova, D.
AU  - Suvajdžić, Nada
AU  - Tomin, D.
AU  - Tošić, Nataša
AU  - Racil, Z.
AU  - Steurer, M.
AU  - Pavlović, Sonja
AU  - Vannucchi, A. M.
AU  - Cazzola, M.
AU  - Gisslinger, H.
AU  - Kralovics, R.
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/823
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies
EP  - 97
SP  - 97
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_823
ER  - 

@conference{
author = "Pudja, A. and Milosević, J. D. and Klampfl, T. and Harutyunyan, A. and Berg, T. and Bagienski, K. and Chen, D. and Gisslinger, B. and Rumi, E. and Malcovati, L. and Pietra, Daniela and Elena, C. and Della Porta, M. G. and Pieri, Lisa and Guglielmelli, Paola and Doubek, M. and Dvorakova, D. and Suvajdžić, Nada and Tomin, D. and Tošić, Nataša and Racil, Z. and Steurer, M. and Pavlović, Sonja and Vannucchi, A. M. and Cazzola, M. and Gisslinger, H. and Kralovics, R.",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies",
pages = "97-97",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_823"
}

Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, D., Elena, C., Della Porta, M. G., Pieri, L., Guglielmelli, P., Doubek, M., Dvorakova, D., Suvajdžić, N., Tomin, D., Tošić, N., Racil, Z., Steurer, M., Pavlović, S., Vannucchi, A. M., Cazzola, M., Gisslinger, H.,& Kralovics, R.. (2015). High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 97-97.
https://hdl.handle.net/21.15107/rcub_imagine_823

Pudja A, Milosević JD, Klampfl T, Harutyunyan A, Berg T, Bagienski K, Chen D, Gisslinger B, Rumi E, Malcovati L, Pietra D, Elena C, Della Porta MG, Pieri L, Guglielmelli P, Doubek M, Dvorakova D, Suvajdžić N, Tomin D, Tošić N, Racil Z, Steurer M, Pavlović S, Vannucchi AM, Cazzola M, Gisslinger H, Kralovics R. High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies. in Haematologica-The Hematology Journal. 2015;100:97-97.
https://hdl.handle.net/21.15107/rcub_imagine_823 .

Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, Daniela, Elena, C., Della Porta, M. G., Pieri, Lisa, Guglielmelli, Paola, Doubek, M., Dvorakova, D., Suvajdžić, Nada, Tomin, D., Tošić, Nataša, Racil, Z., Steurer, M., Pavlović, Sonja, Vannucchi, A. M., Cazzola, M., Gisslinger, H., Kralovics, R., "High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies" in Haematologica-The Hematology Journal, 100 (2015):97-97,
https://hdl.handle.net/21.15107/rcub_imagine_823 .

TY  - CONF
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Suvajdžić-Vuković, Nada
AU  - Tošić, Nataša
AU  - Novković, A.
AU  - Mitrović, M.
AU  - Čolović, Nataša
AU  - Vidović, A.
AU  - Pavlović, Sonja
AU  - Tomin, D.
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/825
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia
EP  - 369
SP  - 369
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_825
ER  - 

@conference{
author = "Virijević, M. and Djunić, I. and Suvajdžić-Vuković, Nada and Tošić, Nataša and Novković, A. and Mitrović, M. and Čolović, Nataša and Vidović, A. and Pavlović, Sonja and Tomin, D.",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia",
pages = "369-369",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_825"
}

Virijević, M., Djunić, I., Suvajdžić-Vuković, N., Tošić, N., Novković, A., Mitrović, M., Čolović, N., Vidović, A., Pavlović, S.,& Tomin, D.. (2015). Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 369-369.
https://hdl.handle.net/21.15107/rcub_imagine_825

Virijević M, Djunić I, Suvajdžić-Vuković N, Tošić N, Novković A, Mitrović M, Čolović N, Vidović A, Pavlović S, Tomin D. Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia. in Haematologica-The Hematology Journal. 2015;100:369-369.
https://hdl.handle.net/21.15107/rcub_imagine_825 .

Virijević, M., Djunić, I., Suvajdžić-Vuković, Nada, Tošić, Nataša, Novković, A., Mitrović, M., Čolović, Nataša, Vidović, A., Pavlović, Sonja, Tomin, D., "Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia" in Haematologica-The Hematology Journal, 100 (2015):369-369,
https://hdl.handle.net/21.15107/rcub_imagine_825 .

TY  - CONF
AU  - Mitrović, M.
AU  - Suvajdžić, Nada
AU  - Elezović, I.
AU  - Bogdanović, A.
AU  - Đorđević, Valentina
AU  - Djunić, I.
AU  - Gvozdenov, Maja
AU  - Čolović, Nataša
AU  - Virijević, M.
AU  - Vidović, A.
AU  - Tomin, D.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/708
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Risk factors for thrombosis in acute promyelocytic leukemia
EP  - S105
SP  - S104
VL  - 133
DO  - 10.1016/S0049-3848(14)50331-3
ER  - 

@conference{
author = "Mitrović, M. and Suvajdžić, Nada and Elezović, I. and Bogdanović, A. and Đorđević, Valentina and Djunić, I. and Gvozdenov, Maja and Čolović, Nataša and Virijević, M. and Vidović, A. and Tomin, D.",
year = "2014",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Risk factors for thrombosis in acute promyelocytic leukemia",
pages = "S105-S104",
volume = "133",
doi = "10.1016/S0049-3848(14)50331-3"
}

Mitrović, M., Suvajdžić, N., Elezović, I., Bogdanović, A., Đorđević, V., Djunić, I., Gvozdenov, M., Čolović, N., Virijević, M., Vidović, A.,& Tomin, D.. (2014). Risk factors for thrombosis in acute promyelocytic leukemia. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 133, S104-S105.
https://doi.org/10.1016/S0049-3848(14)50331-3

Mitrović M, Suvajdžić N, Elezović I, Bogdanović A, Đorđević V, Djunić I, Gvozdenov M, Čolović N, Virijević M, Vidović A, Tomin D. Risk factors for thrombosis in acute promyelocytic leukemia. in Thrombosis Research. 2014;133:S104-S105.
doi:10.1016/S0049-3848(14)50331-3 .

Mitrović, M., Suvajdžić, Nada, Elezović, I., Bogdanović, A., Đorđević, Valentina, Djunić, I., Gvozdenov, Maja, Čolović, Nataša, Virijević, M., Vidović, A., Tomin, D., "Risk factors for thrombosis in acute promyelocytic leukemia" in Thrombosis Research, 133 (2014):S104-S105,
https://doi.org/10.1016/S0049-3848(14)50331-3 . .

TY  - CONF
AU  - Mitrović, M.
AU  - Tošić, Nataša
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Čolović, Nataša
AU  - Kostić, Tatjana 
AU  - Glumac, Irena
AU  - Pavlović, Sonja
AU  - Elezović, I.
AU  - Tomin, D.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/744
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia
EP  - 575
SP  - 575
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_imagine_744
ER  - 

@conference{
author = "Mitrović, M. and Tošić, Nataša and Suvajdžić, Nada and Djunić, I. and Vidović, A. and Virijević, M. and Čolović, Nataša and Kostić, Tatjana  and Glumac, Irena and Pavlović, Sonja and Elezović, I. and Tomin, D.",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia",
pages = "575-575",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_imagine_744"
}

Mitrović, M., Tošić, N., Suvajdžić, N., Djunić, I., Vidović, A., Virijević, M., Čolović, N., Kostić, T., Glumac, I., Pavlović, S., Elezović, I.,& Tomin, D.. (2014). Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 99, 575-575.
https://hdl.handle.net/21.15107/rcub_imagine_744

Mitrović M, Tošić N, Suvajdžić N, Djunić I, Vidović A, Virijević M, Čolović N, Kostić T, Glumac I, Pavlović S, Elezović I, Tomin D. Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia. in Haematologica-The Hematology Journal. 2014;99:575-575.
https://hdl.handle.net/21.15107/rcub_imagine_744 .

Mitrović, M., Tošić, Nataša, Suvajdžić, Nada, Djunić, I., Vidović, A., Virijević, M., Čolović, Nataša, Kostić, Tatjana , Glumac, Irena, Pavlović, Sonja, Elezović, I., Tomin, D., "Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia" in Haematologica-The Hematology Journal, 99 (2014):575-575,
https://hdl.handle.net/21.15107/rcub_imagine_744 .

TY  - CONF
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Tomin, D.
AU  - Suvajdžić-Vuković, Nada
AU  - Čolović, Nataša
AU  - Mitrović, M.
AU  - Arsić-Arsenijević, Valentina
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/745
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Significance of febrile neutropenia risk score in patients with acute myeloid leukemia
EP  - 575
SP  - 574
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_imagine_745
ER  - 

@conference{
author = "Vidović, A. and Virijević, M. and Djunić, I. and Tomin, D. and Suvajdžić-Vuković, Nada and Čolović, Nataša and Mitrović, M. and Arsić-Arsenijević, Valentina and Pavlović, Sonja and Mihaljević, B.",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Significance of febrile neutropenia risk score in patients with acute myeloid leukemia",
pages = "575-574",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_imagine_745"
}

Vidović, A., Virijević, M., Djunić, I., Tomin, D., Suvajdžić-Vuković, N., Čolović, N., Mitrović, M., Arsić-Arsenijević, V., Pavlović, S.,& Mihaljević, B.. (2014). Significance of febrile neutropenia risk score in patients with acute myeloid leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 99, 574-575.
https://hdl.handle.net/21.15107/rcub_imagine_745

Vidović A, Virijević M, Djunić I, Tomin D, Suvajdžić-Vuković N, Čolović N, Mitrović M, Arsić-Arsenijević V, Pavlović S, Mihaljević B. Significance of febrile neutropenia risk score in patients with acute myeloid leukemia. in Haematologica-The Hematology Journal. 2014;99:574-575.
https://hdl.handle.net/21.15107/rcub_imagine_745 .

Vidović, A., Virijević, M., Djunić, I., Tomin, D., Suvajdžić-Vuković, Nada, Čolović, Nataša, Mitrović, M., Arsić-Arsenijević, Valentina, Pavlović, Sonja, Mihaljević, B., "Significance of febrile neutropenia risk score in patients with acute myeloid leukemia" in Haematologica-The Hematology Journal, 99 (2014):574-575,
https://hdl.handle.net/21.15107/rcub_imagine_745 .